Etienne Jornod - Vifor Pharma Chairman
Chairman
Mr. Etienne Jornod is Executive Chairman of the Board of Directors at Vifor Pharma Ltd. since January 1, 2012. He is Chairman of Governance and Nomination Committee and Swiss Healthcare Committee, as well as Member of Scientific and Pharma Committee. Prior to that he acted as Chairman of the Board of Directors, Chief Executive Officer and Member of the Corporationrationrate Executive Committee at the Company from 1996 to 2011. He joined the Company group in 1975, as Junior Product Manager and left the group in 1978. He returned to the Group, in 1981, as Assistant to the General Director and was member of General Direction in 1989. He is Member of the Board of Directors of Alliance Boots. He graduated from Universite de Lausanne with a Bachelors degree in Economics and from Stanford University, where he completed Senior Executive Program. He was also Chairman of the Board of Directors of the Aktiengesellschaft fuer die Neue Zuercher Zeitung. since 2012.
| Age | 64 |
| Tenure | 12 years |
| Phone | 41 58 851 80 00 |
| Web | https://www.viforpharma.com |
Vifor Pharma Management Efficiency
The company has return on total asset (ROA) of 4.6 % which means that it generated a profit of $4.6 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 6.65 %, meaning that it generated $6.65 on every $100 dollars invested by stockholders. Vifor Pharma's management efficiency ratios could be used to measure how well Vifor Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 587.5 M in total debt with debt to equity ratio (D/E) of 0.15, which may suggest the company is not taking enough advantage from borrowing. Vifor Pharma AG has a current ratio of 1.87, which is within standard range for the sector. Debt can assist Vifor Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Vifor Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vifor Pharma AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vifor to invest in growth at high rates of return. When we think about Vifor Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Francis Scricco | Visteon Corp | 69 | |
| Larry Magee | Wabash National | 66 | |
| Laurent Beaudoin | BRP Inc | 78 | |
| Martin Jischke | Wabash National | 77 | |
| David Dauch | American Axle Manufacturing | 59 | |
| James Cracchiolo | Ameriprise Financial | 65 | |
Management Performance
Vifor Pharma AG Leadership Team
Elected by the shareholders, the Vifor Pharma's board of directors comprises two types of representatives: Vifor Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vifor. The board's role is to monitor Vifor Pharma's management team and ensure that shareholders' interests are well served. Vifor Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vifor Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Garidel, member of Board of Director | ||
| David Bevan, CEO Vifor Fresenius Medical Care Renal Pharma Ltd., Member of the Executive Committee | ||
| Daniela BosshardtHengartner, Member of the Board of Directors | ||
| Sue Mahony, Member of the Board of Directors | ||
| Sylvie Gregoire, Director | ||
| Stefan Schulze, President of the Executive Committee, COO | ||
| Christoph Springer, Head of Global Business Development, Member of the Executive Committee | ||
| Hans Frick, Member of the Board of Directors | ||
| Etienne Jornod, Executive Chairman, Chairman of Governane and Nomination Committee, Chairman of Swiss Healthcare Committee and Member of Scientific and Pharma Committee | ||
| Joerg Kneubuehler, Member of the Corporate Executive Committee, CFO | ||
| Stefano Pessina, Member of the Board of Directors | ||
| Michael Puri, Senior Vice President & Head of Global Human Resources, Member of the Executive Committee | ||
| This Schneider, Member of the Board of Directors | ||
| Julien Vignot, Head of Investor Relations | ||
| Scott Garland, President Relypsa, Member of the Executive Committee | ||
| Michel Burnier, Member of the Board of Directors | ||
| Jacques Theurillat, Member of the Board of Directors | ||
| Soeren Tulstrup, Member of the Corporate Executive Committee | ||
| Felix Burkhard, Member of the Corporate Executive Committee | ||
| Gianni Zampieri, Head of Pharma Operations and Vice-CEO of Vifor Pharma | ||
| JeanClaude Clemencon, Member of the Corporate Executive Committee | ||
| Dario Eklund, Chief Commercial Officer, Member of the Executive Committee | ||
| Kim Stratton, Member of the Board of Directors | ||
| Colin Bond, CFO, Member of the Executive Committee | ||
| Romeo Cerutti, member of Board of Directors | ||
| Fritz Hirsbrunner, Head of Investor Relations, Director, Member of Audit and Risk Committee and Member of Swiss Healthcare Committee |
Vifor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Vifor Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 6.65 | |||
| Return On Asset | 4.6 | |||
| Profit Margin | 7.97 % | |||
| Operating Margin | 20.94 % | |||
| Current Valuation | 11.98 B | |||
| Shares Outstanding | 64.86 M | |||
| Shares Owned By Insiders | 0.06 % | |||
| Shares Owned By Institutions | 26.05 % | |||
| Price To Earning | 29.90 X | |||
| Price To Book | 3.29 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Vifor Pharma AG information on this page should be used as a complementary analysis to other Vifor Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |